Eli Lilly and Company Expands Lebanon, Indiana, Manufacturing Operations
06/02/2024
The investment will increase the company’s capacity to manufacture active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide) injection. Initial operations are scheduled for the end of 2026.
“Lilly’s commitment to meeting the demand for our life-changing medicines goes beyond buildings and extends to improving education opportunities and upskilling a global workforce of the future,” said Edgardo Hernandez, executive vice president and president, Lilly Manufacturing Operations. “Academia is a critical partner to both industry and government as we work together to advance innovation in our state and communities around the globe.”
To support the project, the state will partner on infrastructure solutions – road improvements, water, electric and other utilities – as well as workforce development commitments and certain economic incentives tied to the company's achievement of investment and employment goals. The state's workforce development support includes the contribution of land, pending approval, for the construction of a learning and training center that will be part of the larger LEAP industrial development, along with a commitment to work with Lilly to raise capital for its completion.
"Lilly continues to play a transformational role in shaping Indiana's opportunity economy, and I couldn't be more proud about their pole position leadership in developing the LEAP Research and Innovation District in Lebanon, Indiana. Lilly has long been driving global innovation and economic growth that will be felt for decades here at home," noted Indiana Governor Eric J. Holcomb. "As an international company, headquartered in Indiana, Lilly had a world of options to consider before making this investment, and choosing Indiana once again reinforces the incredible environment we've cultivated and the talented workforce we have to carry Lilly's success forward. I can't wait to see the incredible benefits this investment leads to for patients around the world, knowing they were made in Indiana."
Since 2020, Lilly noted it has committed more than $16 billion to develop new manufacturing sites in the U.S. and Europe. New locations outside Indiana include; Research Triangle Park and Concord, North Carolina; Limerick, Ireland; and Alzey, Germany.
Project Announcements
Amgen Expands New Albany, Ohio, Manufacturing Operations
04/28/2025
United Kingdom-Based Balmoral Tanks Plans Mentor, Ohio, Operations
04/28/2025
E & E Hardwoods Expands Bell County, Kentucky, Saw Mill Operations
04/27/2025
Aegis Sortation Expands Louisville, Kentucky, Operations
04/26/2025
Process Machinery Expands Shelby County, Kentucky, Production Operations
04/26/2025
HL Mechatronics Expands Williams Township, Michigan, Operations
04/26/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
The Location Economics of Advanced Nuclear
Q1 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
NEW NIMBYism: A Threat to The U.S. Economy
Q4 2024
-
Power, Policy, and Site Selection in 2025
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
Designing Beyond the Assembly Line
Q1 2025